Close Menu

NEW YORK (GenomeWeb News) – GlaxoSmithKline today said that it has reached an agreement to acquire the remaining 80 percent of proteomics firm Cellzome that it didn't already own for £61 million ($99 million).

The deal will provide GSK with state-of-the-art proteomic mass spectrometry and screening capabilities, the UK drug firm said. It will use Cellzome's technologies to assess drug interactions with target proteins and to help identify potential safety issues earlier in the drug discovery process.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics.